Infinity Bio announced the appointment of Brian McKelligon as CEO on March 18, 20261245.
McKelligon has extensive experience scaling life sciences platforms, including as former CEO of Akoya Biosciences, VP at 10x Genomics, and roles at Ion Torrent2.
Infinity Bio pioneers MIPSA technology to decode the antibody reactome, mapping immune responses to viruses, human proteins, allergens, and more via libraries like HuSIGHT™, VirSIGHT™, EnviroSIGHT™, and MuSIGHT™1.
The appointment aims to drive growth, global expansion, and commercial acceleration following recent $8M Series A financing led by Illumina Ventures16.
Investors from PTX Capital and Illumina Ventures praised McKelligon's track record in commercializing technologies12.
Sources:
1. https://www.businesswire.com/news/home/20260318063466/en/Infinity-Bio-Appoints-Brian-McKelligon-as-Chief-Executive-Officer
2. https://briefglance.com/articles/infinity-bio-taps-new-ceo-to-scale-breakthrough-immune-mapping-tech
4. https://app.fundz.net/executives/infinity-bio-hired-bd2d
5. https://lasvegassun.com/news/2026/mar/18/infinity-bio-appoints-brian-mckelligon-as-chief-ex/
6. https://www.businesswire.com/news/home/20250618065841/en/Infinity-Bio-Closes-$8M-Series-A-Financing-Led-by-Illumina-Ventures-to-Expand-Leadership-in-Antibody-Reactome-Profiling